The pooled HR for AML transformation was 1.89 (95% CI: 1.32–2.71, with a p-value of 0.0005, I2 = 0%) for SRSF2-mutated patients compared with unmutated patients, revealing that patients with SRSF2 mutations have a more rapid and frequent transformation to AML. This evidence concerns the gene SRSF2 and acute myeloid leukemia.